267 related articles for article (PubMed ID: 32100261)
21. Early Serum HBsAg Drop Is a Strong Predictor of HBeAg Seroconversion and HBsAg Loss to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients with Prior Nucleos(t)ide Analogue Exposure.
Chen Q; Zhang J; Huang J; Quan B; Wu X; Deng S; Han W
Med Sci Monit; 2019 Jun; 25():4665-4674. PubMed ID: 31230063
[TBL] [Abstract][Full Text] [Related]
22. Experimental HBsAg/anti-HBs complex assay for prediction of HBeAg loss in chronic hepatitis B patients treated with pegylated interferon and adefovir.
de Niet A; Jansen L; Zaaijer HL; Klause U; Takkenberg B; Janssen HL; Chu T; Petric R; Reesink HW
Antivir Ther; 2014; 19(3):259-67. PubMed ID: 24256626
[TBL] [Abstract][Full Text] [Related]
23. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
25. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
26. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
Luo XD; Chen XF; Zhou Y; Chen XP
J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
[TBL] [Abstract][Full Text] [Related]
27. [Low-levels of HBsAg quantification at 48-week in HBeAg-negative chronic hepatitis B patients are the advantageous population for HBsAg clearance].
Yan YJ; Wang XX; Cao ZH; Lu JF; Jin Y; He ZM; Geng N; Ren S; Ma LN; Chen XY
Zhonghua Gan Zang Bing Za Zhi; 2018 Nov; 26(11):813-818. PubMed ID: 30616314
[No Abstract] [Full Text] [Related]
28. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
29. [Optimal treatment regimen for patients with HBeAg-positive chronic hepatitis B after suboptimal response to 24 weeks of Peg-IFN α-2a].
Luo XD; Chen XP; Chen XF
Zhonghua Gan Zang Bing Za Zhi; 2017 Dec; 25(12):896-901. PubMed ID: 29325289
[No Abstract] [Full Text] [Related]
30. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.
Li GJ; Yu YQ; Chen SL; Fan P; Shao LY; Chen JZ; Li CS; Yi B; Chen WC; Xie SY; Mao XN; Zou HH; Zhang WH
Antimicrob Agents Chemother; 2015 Jul; 59(7):4121-8. PubMed ID: 25941216
[TBL] [Abstract][Full Text] [Related]
31. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
32. Serum HBV RNA correlated with intrahepatic cccDNA more strongly than other HBV markers during peg-interferon treatment.
Wang X; Chi X; Wu R; Xu H; Gao X; Yu L; Liu L; Zhang M; Tan Y; Niu J; Jin Q
Virol J; 2021 Jan; 18(1):4. PubMed ID: 33407619
[TBL] [Abstract][Full Text] [Related]
33. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial).
Ning Q; Han M; Sun Y; Jiang J; Tan D; Hou J; Tang H; Sheng J; Zhao M
J Hepatol; 2014 Oct; 61(4):777-84. PubMed ID: 24915612
[TBL] [Abstract][Full Text] [Related]
34. Baseline and kinetics of serum hepatitis B virus RNA predict response to pegylated interferon-based therapy in patients with hepatitis B e antigen-negative chronic hepatitis B.
Limothai U; Chuaypen N; Poovorawan K; Chotiyaputta W; Tanwandee T; Poovorawan Y; Tangkijvanich P
J Viral Hepat; 2019 Dec; 26(12):1481-1488. PubMed ID: 31446638
[TBL] [Abstract][Full Text] [Related]
35. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis B.
Farag MS; van Campenhout MJH; Pfefferkorn M; Fischer J; Deichsel D; Boonstra A; van Vuuren AJ; Ferenci P; Feld JJ; Berg T; Hansen BE; van Bömmel F; Janssen HLA
Clin Infect Dis; 2021 Jan; 72(2):202-211. PubMed ID: 31912157
[TBL] [Abstract][Full Text] [Related]
37. The comparison of the efficacy of pegylated interferon α-2a and α-2b in chronic hepatitis B patients.
Dogan UB; Golge N; Akin MS
Eur J Gastroenterol Hepatol; 2013 Nov; 25(11):1312-6. PubMed ID: 23652913
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study.
Huang Z; Zhao Z; Zheng Y; Peng L; Lin C; Deng H; Gao Z
J Viral Hepat; 2013 Apr; 20 Suppl 1():52-7. PubMed ID: 23458525
[TBL] [Abstract][Full Text] [Related]
39. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.
Fried MW; Piratvisuth T; Lau GK; Marcellin P; Chow WC; Cooksley G; Luo KX; Paik SW; Liaw YF; Button P; Popescu M
Hepatology; 2008 Feb; 47(2):428-34. PubMed ID: 18220290
[TBL] [Abstract][Full Text] [Related]
40. [Quantifiable changes in HBeAg expression predict therapeutic efficacy of peg-interferon alfa-2a in patients with HBeAg-positive chronic hepatitis B].
Ji YJ; Li FF; Ren WH; Zhu YH; Qin CY
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):335-9. PubMed ID: 24025132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]